OCGN Ocugen, Inc.

NASDAQ
$1.35

Ocugen, Inc. (OCGN) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.0% since its last earnings release on August 6, 2026.

Ocugen Missed Consensus Estimates
Thursday, August 6, 2026 · 7:02 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:30 AM ET
Earnings Whisper
-
vs ($0.06)
Rev est $1.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.32

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.

Sector

Healthcare

Industry

Biotechnology